AstraZeneca plc (AZN) Stock Rating Reaffirmed by Liberum Capital

Liberum Capital restated their hold rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Wednesday. They currently have a GBX 5,000 ($65.98) price target on the biopharmaceutical company’s stock.

Several other research analysts have also weighed in on AZN. J P Morgan Chase & Co set a GBX 4,200 ($55.42) price objective on shares of AstraZeneca plc and gave the stock a neutral rating in a research note on Wednesday, August 9th. Barclays PLC restated an overweight rating and set a GBX 5,500 ($72.58) price objective on shares of AstraZeneca plc in a research note on Monday, August 7th. Shore Capital restated a hold rating on shares of AstraZeneca plc in a research note on Tuesday, October 31st. Jefferies Group LLC lowered their price objective on shares of AstraZeneca plc from GBX 4,900 ($64.66) to GBX 4,400 ($58.06) and set a hold rating on the stock in a research note on Tuesday, August 1st. Finally, Investec upgraded shares of AstraZeneca plc from a hold rating to a buy rating and lowered their price objective for the stock from GBX 5,000 ($65.98) to GBX 4,900 ($64.66) in a research note on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of Hold and an average target price of GBX 5,183.55 ($68.40).

AstraZeneca plc (AZN) opened at GBX 5,157.64 ($68.06) on Wednesday. AstraZeneca plc has a 52 week low of GBX 3,996 ($52.73) and a 52 week high of GBX 5,520 ($72.84).

COPYRIGHT VIOLATION NOTICE: “AstraZeneca plc (AZN) Stock Rating Reaffirmed by Liberum Capital” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.com-unik.info/2017/11/05/astrazeneca-plc-azn-stock-rating-reaffirmed-by-liberum-capital.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

What are top analysts saying about AstraZeneca plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AstraZeneca plc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit